DNASE1L3 and autoimmune disease: In conclusion, our studies suggest that enhancing the plasma activity of DNASE1 and DNASE1L3 with our bioavailable enzyme biologic is likely to carry significant therapeutic benefit in patients with autoimmune disease associated with impaired DNASE1L3 activity.